metformin has been researched along with Degenerative Diseases, Central Nervous System in 17 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the novel linkage between a Western diet combining high saturated fat, sugar, and salt (HFSS) and neurological dysfunctions during aging as well as Metformin intervention, we assessed cerebral cortex abnormalities associated with sensory and motor dysfunctions and cellular and molecular insights in brains using HFSS-fed mice during aging." | 8.02 | A high fat, sugar, and salt Western diet induces motor-muscular and sensory dysfunctions and neurodegeneration in mice during aging: Ameliorative action of metformin. ( Bazan, NG; Duong, QA; Hong, S; Lu, Y; Nagayach, A; Peng, H; Pham, NB; Vuong, CA, 2021) |
| "Metformin is a pleiotropic drug, modulating different targets such as AMPK, insulin signalling and many others." | 6.82 | Metformin to treat Huntington disease: A pleiotropic drug against a multi-system disorder. ( Casterá, F; Gómez-Escribano, AP; Herrero, MJ; Millán, JM; Peiró, C; Tortajada-Pérez, J; Trujillo-Del Río, C; Vázquez-Manrique, RP, 2022) |
| "Metformin has failed to demonstrate a beneficial effect on NDs." | 6.66 | Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis. ( Jiang, N; Li, Y; Ping, F, 2020) |
| " The effects of exposure duration and dosage on dementia and PD occurrence were also observed." | 5.46 | Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. ( Hu, CJ; Huang, KW; Kao, CH; Kuan, YC; Lin, CL, 2017) |
| "To explore the novel linkage between a Western diet combining high saturated fat, sugar, and salt (HFSS) and neurological dysfunctions during aging as well as Metformin intervention, we assessed cerebral cortex abnormalities associated with sensory and motor dysfunctions and cellular and molecular insights in brains using HFSS-fed mice during aging." | 4.02 | A high fat, sugar, and salt Western diet induces motor-muscular and sensory dysfunctions and neurodegeneration in mice during aging: Ameliorative action of metformin. ( Bazan, NG; Duong, QA; Hong, S; Lu, Y; Nagayach, A; Peng, H; Pham, NB; Vuong, CA, 2021) |
| "Metformin is a pleiotropic drug, modulating different targets such as AMPK, insulin signalling and many others." | 2.82 | Metformin to treat Huntington disease: A pleiotropic drug against a multi-system disorder. ( Casterá, F; Gómez-Escribano, AP; Herrero, MJ; Millán, JM; Peiró, C; Tortajada-Pérez, J; Trujillo-Del Río, C; Vázquez-Manrique, RP, 2022) |
| "Both metformin and aspirin have been associated with improved cognitive outcomes." | 2.72 | AMPK activators for the prevention and treatment of neurodegenerative diseases. ( Neumann, NR; Thompson, DC; Vasiliou, V, 2021) |
| "Metformin has failed to demonstrate a beneficial effect on NDs." | 2.66 | Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis. ( Jiang, N; Li, Y; Ping, F, 2020) |
| "Metformin treatment (300 mg/kg/day, ip) was started concurrently with rotenone administration and continued for 10 days." | 1.56 | Metformin protects rotenone-induced dopaminergic neurodegeneration by reducing lipid peroxidation. ( Agar, A; Aslan, M; Nemutlu-Samur, D; Ozbey, G; Parlak, H; Tanriover, G; Yildirim, S, 2020) |
| " The effects of exposure duration and dosage on dementia and PD occurrence were also observed." | 1.46 | Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. ( Hu, CJ; Huang, KW; Kao, CH; Kuan, YC; Lin, CL, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 10 (58.82) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, S | 1 |
| Nagayach, A | 1 |
| Lu, Y | 1 |
| Peng, H | 1 |
| Duong, QA | 1 |
| Pham, NB | 1 |
| Vuong, CA | 1 |
| Bazan, NG | 1 |
| Neumann, NR | 1 |
| Thompson, DC | 1 |
| Vasiliou, V | 1 |
| Zhang, Y | 2 |
| Shi, X | 1 |
| Han, J | 1 |
| Lin, B | 1 |
| Peng, W | 1 |
| Mei, Z | 1 |
| Lin, Y | 1 |
| Trujillo-Del Río, C | 1 |
| Tortajada-Pérez, J | 1 |
| Gómez-Escribano, AP | 1 |
| Casterá, F | 1 |
| Peiró, C | 1 |
| Millán, JM | 1 |
| Herrero, MJ | 1 |
| Vázquez-Manrique, RP | 1 |
| Al-Kuraishy, HM | 1 |
| Al-Gareeb, AI | 1 |
| Saad, HM | 1 |
| Batiha, GE | 1 |
| Ozbey, G | 1 |
| Nemutlu-Samur, D | 1 |
| Parlak, H | 1 |
| Yildirim, S | 1 |
| Aslan, M | 1 |
| Tanriover, G | 1 |
| Agar, A | 1 |
| Ping, F | 1 |
| Jiang, N | 1 |
| Li, Y | 1 |
| Diaz, A | 1 |
| Muñoz-Arenas, G | 1 |
| Venegas, B | 1 |
| Vázquez-Roque, R | 1 |
| Flores, G | 1 |
| Guevara, J | 1 |
| Gonzalez-Vergara, E | 1 |
| Treviño, S | 1 |
| Sharma, S | 1 |
| Nozohouri, S | 1 |
| Vaidya, B | 1 |
| Abbruscato, T | 1 |
| Rana, T | 1 |
| Behl, T | 1 |
| Sehgal, A | 1 |
| Mehta, V | 1 |
| Singh, S | 1 |
| Bhatia, S | 1 |
| Al-Harrasi, A | 1 |
| Bungau, S | 1 |
| Kuan, YC | 1 |
| Huang, KW | 1 |
| Lin, CL | 1 |
| Hu, CJ | 1 |
| Kao, CH | 1 |
| Gault, VA | 1 |
| Hölscher, C | 1 |
| Tao, L | 1 |
| Li, D | 1 |
| Liu, H | 1 |
| Jiang, F | 1 |
| Xu, Y | 1 |
| Cao, Y | 1 |
| Gao, R | 1 |
| Chen, G | 1 |
| Scheen, AJ | 1 |
| Lefèbvre, PJ | 1 |
| Paquot, N | 1 |
| Shi, Q | 1 |
| Liu, S | 1 |
| Fonseca, VA | 1 |
| Thethi, TK | 1 |
| Shi, L | 1 |
| Reddy, VP | 1 |
| Beyaz, A | 1 |
| El-Mir, MY | 1 |
| Detaille, D | 1 |
| R-Villanueva, G | 1 |
| Delgado-Esteban, M | 1 |
| Guigas, B | 1 |
| Attia, S | 1 |
| Fontaine, E | 1 |
| Almeida, A | 1 |
| Leverve, X | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for metformin and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
AMPK activators for the prevention and treatment of neurodegenerative diseases.
Topics: AMP-Activated Protein Kinases; Animals; Aspirin; Enzyme Activators; Humans; Metformin; Momordica cha | 2021 |
Metformin and the risk of neurodegenerative diseases in patients with diabetes: A meta-analysis of population-based cohort studies.
Topics: Cohort Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2022 |
Metformin to treat Huntington disease: A pleiotropic drug against a multi-system disorder.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Humans; Huntington Disease; Metformin; Neurodegene | 2022 |
Long-term use of metformin and Alzheimer's disease: beneficial or detrimental effects.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Diabetes Mellitus, Type 2; Disease Models, | 2023 |
Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neurodegenerative Diseases; Thiaz | 2020 |
Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke.
Topics: Aging; Animals; Brain Ischemia; Drug Repositioning; Humans; Hypoglycemic Agents; Metformin; Neurodeg | 2021 |
Exploring the Role of Autophagy Dysfunction in Neurodegenerative Disorders.
Topics: Animals; Autophagosomes; Autophagy; Cell Survival; Humans; Lysosomes; Metformin; MTOR Inhibitors; Ne | 2021 |
GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes.
Topics: Animals; Blood Glucose; Brain; Cognition; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucago | 2018 |
Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases.
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Guanidines; Humans; Hyp | 2006 |
8 other studies available for metformin and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
A high fat, sugar, and salt Western diet induces motor-muscular and sensory dysfunctions and neurodegeneration in mice during aging: Ameliorative action of metformin.
Topics: Aged; Aging; Animals; Diet, Carbohydrate Loading; Diet, High-Fat; Diet, Western; Disease Models, Ani | 2021 |
Metformin protects rotenone-induced dopaminergic neurodegeneration by reducing lipid peroxidation.
Topics: alpha-Synuclein; Animals; Dopamine; Dopaminergic Neurons; Lipid Peroxidation; Male; Metformin; Mice; | 2020 |
Metforminium Decavanadate (MetfDeca) Treatment Ameliorates Hippocampal Neurodegeneration and Recognition Memory in a Metabolic Syndrome Model.
Topics: Animals; Catalase; Drug Combinations; Hippocampus; Inflammation; Male; Memory; Metabolic Syndrome; M | 2021 |
Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.
Topics: Aged; Comorbidity; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up St | 2017 |
Neuroprotective effects of metformin on traumatic brain injury in rats associated with NF-κB and MAPK signaling pathway.
Topics: Animals; Brain; Brain Injuries, Traumatic; Disease Models, Animal; Extracellular Signal-Regulated MA | 2018 |
[Reappraisal of metformin : less restrictions and more potential indications].
Topics: Contraindications, Drug; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglycemic Agents; Met | 2018 |
Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus.
Topics: Aged; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Longit | 2019 |
Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cells, Cultured; Cerebral Cortex; Cyclosporin | 2008 |